Trastuzumab Deruxtecan (T-DXd) is a medication used in this clinical trial to treat HER2-positive metastatic breast cancer. It is designed to target and attach to the HER2 protein on cancer cells, delivering chemotherapy directly to the cancer cells to help stop their growth and spread.

Pertuzumab is another medication used in the trial, often in combination with other treatments. It works by attaching to the HER2 protein on cancer cells, similar to Trastuzumab Deruxtecan, and helps to block the signals that encourage cancer cell growth.

Taxane is a type of chemotherapy drug included in the trial. It works by interfering with the normal function of microtubules during cell division, which helps to stop the growth of cancer cells.

Trastuzumab is a medication that targets the HER2 protein on cancer cells. It is used in combination with other drugs in this trial to help slow or stop the growth of cancer cells that have too much HER2 protein.

HER2-positive metastatic breast cancer – This is a type of breast cancer characterized by the overexpression of the HER2 protein, which promotes the growth of cancer cells. It is considered metastatic when the cancer has spread beyond the breast to other parts of the body. The disease often progresses through stages, starting from localized tumors in the breast and potentially advancing to distant organs such as the liver, lungs, or brain. The presence of HER2-positive cancer cells can lead to more aggressive tumor growth compared to other types of breast cancer. As the disease progresses, patients may experience symptoms related to the spread of cancer, such as pain or organ dysfunction, depending on the areas affected. The progression of the disease is typically monitored through imaging studies and clinical assessments.